Vorolanib for advanced lung cancer after other treatments
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that has spread or returned after at least two prior treatments.
- Your cancer has either no driver gene mutations, or if it does, you have already tried and not responded to the appropriate targeted therapy.
- You are in generally good health (able to care for yourself) and expected to live at least 3 months.
- Your liver, kidney, and blood counts are within normal limits.
- You have not taken certain other anti-angiogenic drugs (like anlotinib or apatinib) before.
- You do not have uncontrolled brain metastases or a history of significant bleeding or blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This trial tests whether giving treatment before surgery (neoadjuvant therapy) can help people with stage III lung cancer that has certain rare gene changes. The goal is to see if this approach can shrink the tumor enough to allow surgery.
This trial tests a targeted therapy pill, vorolanib, for people with advanced kidney cancer that has clear cell features and has gotten worse after initial treatment. It may offer a new option when standard second-line treatments are not working.
This trial tests two drugs together—vorolanib (a pill that targets blood vessels in tumors) and sintilimab (an immunotherapy that helps your immune system fight cancer)—for people with advanced kidney cancer whose prior immunotherapy combination stopped working.
This trial tests a combination of two drugs, Vorolanib and Cadonilimab, for people with advanced or metastatic clear cell kidney cancer who have not had prior treatment. It aims to see if the combination shrinks the cancer and how safe it is.
Hear when a new Advanced Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.